The Roche Q3 2026 results show group sales of CHF 16.13 billion, up 7% at constant exchange rates and ahead of the company-compiled consensus of CHF 15.75 billion, according to the figures reported on 22 October 2026. The headline beat was led by the multiple sclerosis drug Ocrevus, while sales of the asthma and allergy medicine Xolair fell short of expectations after a lower-priced competitor reached the US market.
Key takeaways from the Roche Q3 2026 results
- Group sales were CHF 16.13 billion, up 7% at constant exchange rates (CER), against consensus of CHF 15.75 billion.
- Ocrevus sales rose 9% at constant currencies to CHF 1.84 billion.
- Xolair sales were CHF 848 million against expectations of about CHF 925 million, after the first cheaper copy launched.
- Diagnostics sales rose 5% to CHF 3.54 billion.
- Roche reaffirmed its outlook of mid-single-digit group sales growth for 2026 and is expanding external licensing.
Roche Q3 2026 results: the numbers in context
The company reported sales growth of 7% at constant exchange rates and 8% in Swiss francs for the quarter, and 6% at constant rates for the first nine months, according to its announcement headline. The company site is roche.com/investors. North America accounts for nearly half of group revenue, and a stronger dollar against the franc eased the currency drag, according to a wire-service report. China posted double-digit declines, though the drag from its pricing reforms is easing.
An analyst at Jefferies described the quarter as cosmetically ahead of forecasts but, once underlying numbers are considered, closer to a miss, and attributed part of the revenue to a new resource planning system. That is one analyst’s view, not a company statement. Roche’s own description is of continued strong momentum.
Ocrevus carries the Roche Q3 2026 results
Ocrevus, Roche’s multiple sclerosis therapy, grew 9% at constant currencies to CHF 1.84 billion. It is one of the group’s best-selling products. A trade-press report notes that Ocrevus and the cancer drug Tecentriq are due to face generic competition by 2030, with the haemophilia drug Hemlibra following in the early part of the next decade. We have not seen Roche’s own patent-expiry schedule, so those timings are attributed to that report.
Xolair competition and the Roche Q3 2026 results
Xolair generated CHF 848 million in the quarter. Expectations cited in reports ranged from “well over CHF 900 million” to about CHF 925 million, and one analyst forecast CHF 972 million. By our own arithmetic, the shortfall against the CHF 925 million figure is about CHF 77 million, or roughly 8%. The reports link the miss to the launch of the first lower-priced copy of Xolair in the US this month, but they do not agree on naming the competing product, and we do not name one.
Lower-priced copies of biologic medicines are known as biosimilars, and the FDA explains how they are approved on its FDA biosimilars page. Acumen Research and Consulting estimates in its report Biosimilars Market Size, Share, Analysis, Trends and Forecast 2024 to 2032 that the global biosimilars market was worth USD 26.7 billion in 2023 and will reach USD 113.2 billion by 2032, a compound annual growth rate of 17.5% for 2024 to 2032. The report also states that monoclonal antibodies are expected to dominate the biosimilars market. Xolair is a monoclonal antibody, which makes the segment relevant, although the Acumen figures cover biosimilars as a whole and not Xolair.
Pipeline and deals behind the Roche Q3 2026 results
A trade-press report says the breast cancer pill giredestrant has an FDA decision expected by 18 December, and that executives see it as a possible future best seller in a crowded field. Roche has said obesity drugs and giredestrant could generate combined peak annual sales of about USD 9 billion, and the experimental multiple sclerosis drug fenebrutinib is awaiting an FDA answer. On deals, a reported licensing agreement with China’s Hansoh Pharma is worth more than USD 15 billion in total, with CHF 400 million upfront, according to reports. Chief executive Thomas Schinecker said about half of Roche’s external licensing deals over four years were made in the US and half in China and Asia.
General background: why Roche Q3 2026 results beats can mislead
Revenue can beat consensus because of currency, accounting changes or one-off items, so analysts compare underlying growth by product. Patent expiries make this more important, because a brand’s sales can drop quickly when lower-priced versions arrive and insurers update coverage. Related coverage is in our pharmaceutical news.
Our analysis: what the Roche Q3 2026 results tell us
In our assessment, the quarter shows a company with strong momentum in newer products and an early example of the pricing pressure its older medicines will face. The Xolair gap is small in group terms, but it is the first real test of how fast a lower-priced competitor can take share. Whether it signals broader pressure is not something the reports establish.
Nothing in this article is investment advice, and we make no forecast for the share price or for 2027 sales.
What is not disclosed in the Roche Q3 2026 results coverage
- Full-year guidance beyond the reaffirmed mid-single-digit growth.
- The name and pricing of the competing Xolair product in the sources we reviewed.
- How much of the quarter’s revenue came from the new planning system, as the analyst suggested.
- Pharmaceuticals division sales, which were not in the reports we read.
Risks and caveats of the Roche Q3 2026 results
The figures come from the company announcement headline and from wire and trade-press reports that sometimes differ on consensus levels. Analyst comments are opinions. This article is news reporting and not investment advice.
What to watch next after the Roche Q3 2026 results
- The FDA decision on giredestrant by 18 December.
- Xolair sales in the fourth quarter as the competitor expands.
- New licensing deals, particularly from China.
- Any change to the 2026 outlook.
FAQ
What were the Roche Q3 2026 results?
Group sales of CHF 16.13 billion, up 7% at constant exchange rates, ahead of consensus of CHF 15.75 billion.
Why did Xolair miss?
Reports link the CHF 848 million result to the launch of the first lower-priced copy in the US.
How did Ocrevus do?
Sales rose 9% at constant currencies to CHF 1.84 billion.
How we reported this: we relied on the company announcement, wire and trade-press reports, and the Acumen Research and Consulting report cited above, and attributed every figure. Last updated 23 October 2026. This is news reporting and not advice.